Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Research
Biotech
Dana-Farber oncologist Anthony Letai tapped to direct NCI
Work led by Letai resulted in the development of AbbVie and Roche’s Venclexta (venetoclax), which was first approved by the FDA in 2016 for leukemia.
Darren Incorvaia
Sep 30, 2025 5:50am
HHS division refers Harvard for potential debarment
Sep 29, 2025 4:59pm
BioLineRx forges joint cancer venture with Norwegian biotech
Sep 29, 2025 11:22am
Fatty acid eye injections restore vision in old mice
Sep 26, 2025 2:10pm
Biogen discontinues all AAV gene therapy work
Sep 26, 2025 11:04am
ARPA-H unveils programs to develop custom gene editing therapies
Sep 26, 2025 10:41am
